Scientific Library

The synergistic combination of Poly(ADP-ribose) polymerases (PARP) and Topoisomerase I (Top1) inhibitors most beneficial on endonuclease-deficient cancer cells in cancer therapies ?

This is one

A crosstalk between cancer and immune cells is established during cancers. The immune system is able to fight against tumour cells (see my previous post "Immunosurveillance: Crosstalk between cancer and

Tumour immune evasion can be mediated by a complex set of interaction involving p53, miR-34 and PDL1. This is the conclusion of a work by Cortez et al. and recently published in JCNI .

The

PD-1:PD:-L1 immune checkpoint pathway targeting immunotherapies have shown great potential for many cancer patients. Recently, The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab

As discussed previously in our recent Drug Discovery post, Immunotherapy is one of the central research fields for various disease treatments and also certain cancers. A major regulator

Recently, BPS Bioscience have released a new Adenosine A2A Receptor (A2AR / ADORA2A) Functional Recombinant Cell Line for screening A2AR agonists and antagonists. An excellent means to

Developing new therapeutic agents to boost the immune system and avoid the escape of diseased cells from the natural defenses is the common goal of all researchers in Immunotherapy. To greatly reduce time

Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread to become the major health issue of the past two years. But it's also a research field of interest